Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) )

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event - ( MOVE-Lp(a) ) - J2O-MC-EKBG

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031250354

Enrollment

10450

Registered

2025-09-10

Start date

2025-10-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elevated Lp(a) Atherosclerotic Cardiovascular Disease (ASCVD)

Interventions

Drug: Muvalaplin Administered orally Other Names:LY3473329 (Study Arms) Experimental: Muvalaplin Participants will receive muvalaplin orally.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Have Lp(a) >=175 nanomoles per liter (nmol/L) Meet one of the following criteria: - Have had a prior atherosclerotic cardiovascular disease (ASCVD) event (such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body) within 10 years prior to screening - Are at risk for a first ASCVD event, defined as one or more of the following: - Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without a history of ASCVD event - A high coronary artery calcium (CAC) score - Reduced kidney function with diabetes - Combination(s) of high risk factors

Exclusion criteria

Exclusion criteria: - Have experienced a major cardiovascular event or surgery, such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body, within 90 days prior to screening or occurring between screening and randomization - Are planning or expected to undergo a procedure to restore blood flow in the arteries or a major heart surgery during the study - Have uncontrolled high blood pressure - Have New York Heart Association (NYHA) class III or IV heart failure - Have undergone a procedure to remove cholesterol from the blood within 90 days of screening, or have a planned procedure during the study - Have severe kidney impairment - Have had cancer within 5 years prior to screening

Design outcomes

Primary

Measure	Time frame
1. Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint Time to first event in a MACE-4 composite endpoint, comprised of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent coronary revascularization. [Time Frame: Baseline up to End of Study (About 5.25 Years)]	—

Countries

Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Romania, Slovakia, South Korea, Spain, Taiwan, United Kingdom, United States

Contacts

Public ContactTrial Guide Call Center

Eli Lilly Japan K.K.

LTG_CallCenter@lists.lilly.com+81-120-023-812

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026